Bristol Myers deploys Anthropic’s Claude AI to accelerate drug discovery
Bristol Myers Squibb has partnered with Anthropic to implement the Claude AI models across its global operations. This deployment will affect over 30,000 employees and is designed to enhance various processes, including drug discovery and clinical trials. The initiative follows a three-year investment in AI technology by the company.
- ▪Bristol Myers Squibb is rolling out Claude AI as an enterprise-wide intelligence layer.
- ▪The deployment will impact over 30,000 employees across the company.
- ▪The partnership is part of a three-year investment in AI technology by Bristol Myers.
- ▪Claude AI will assist in tasks ranging from drug discovery to manufacturing monitoring.
- ▪This is one of the largest enterprise AI deployments in the pharmaceutical industry.
Opening excerpt (first ~120 words) tap to expand
Bristol Myers deploys Anthropic’s Claude AI to accelerate drug discovery The pharma giant is rolling out Claude across 30,000 employees as an enterprise-wide 'intelligence layer' for everything from clinical trials to manufacturing. Share Add us on Google by Editorial Team May. 20, 2026 window.sevioads = window.sevioads || []; var sevioads_preferences = []; sevioads_preferences[0] = {}; sevioads_preferences[0].zone = "01f21ccf-2092-46b1-9ac7-8c44cc782e0f"; sevioads_preferences[0].adType = "native"; sevioads_preferences[0].inventoryId = "c5700508-581b-472c-8fdd-a931cdbfc8e1"; sevioads_preferences[0].accountId = "1e47efc1-ec2d-4fca-a8b9-354e249e5095"; sevioads.push(sevioads_preferences); Bristol Myers Squibb just made one of the largest enterprise AI bets in pharmaceutical history,…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Crypto Briefing.
Discussion
0 commentsMore from Crypto Briefing
